Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Morphomolecular Pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma.
Am J Pathol
September 2024
Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:
Cholangiocarcinomas are a highly heterogeneous group of malignancies that, despite recent progress in the understanding of their molecular pathogenesis and clinical management, continue to pose a major challenge to public health. The traditional view posits that cholangiocarcinomas derive from the neoplastic transformation of cholangiocytes lining the biliary tree. However, increasing genetic and experimental evidence has recently pointed to a more complex, and nuanced, scenario for the potential cell of origin of cholangiocarcinomas.
View Article and Find Full Text PDFMRI features of combined hepatocellular-cholangiocarcinoma.
Abdom Radiol (NY)
January 2025
Department of Radiology, Lahey Hospital and Medical Center, Burlington, MA, USA.
Article Synopsis
- Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare and aggressive liver tumor with a worse prognosis compared to hepatocellular carcinoma (HCC) and similar to intrahepatic cholangiocarcinoma (iCCA).
- There is limited MRI literature regarding cHCC-CCA, making it a challenging diagnosis; however, specific imaging patterns can help distinguish it from other liver tumors.
- Tumor markers might be useful for identification, and sampling challenges arise due to intratumoral heterogeneity, which can lead to misdiagnosis if biopsies don't capture both histologic components.
Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.
BMJ Case Rep
May 2024
Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
A woman in her 60s was diagnosed with a metastatic, unresectable rare histological type of liver cancer; combined hepatocellular cholangiocarcinoma. She had palliative chemotherapy, initially with gemcitabine and cisplatin, and then with oxaliplatin, L-folinic acid and fluorouracil. Both treatment strategies demonstrated disease progression, and somatic mutation profiling revealed no actionable mutations.
View Article and Find Full Text PDFComplex phenotypic heterogeneity of combined hepatocellular-cholangiocarcinoma with a homogenous promoter mutation.
Am J Transl Res
February 2024
Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine Tokyo, Japan.
To clarify the mechanism underlying the development and poor prognosis of combined hepatocellular-cholangiocarcinoma (cHCC-CCA), we characterized liver cancer driver mutations and poor prognostic markers in both the HCC and intrahepatic CCA (iCCA) components of a cHCC-CCA tumor. The telomerase reverse transcriptase () promoter mutation C228T was quantified by digital polymerase chain reaction using DNA from multiple microdissected cancer components of a single cHCC-CCA nodule. The protein expression of cancer-related markers, including TERT, was examined by serial thin-section immunohistochemistry and double-staining immunofluorescence.
View Article and Find Full Text PDFUpdate on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.
J Clin Transl Hepatol
February 2024
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a unique type of liver tumor that contains both hepatocellular carcinoma and cholangiocarcinoma components within a single tumor. The fifth edition of the World Health Organization classification provides a definition and diagnostic criteria for cHCC-CCA. However, the heterogeneous histomorphology and presentation resulting from variation of the proportion of each component poses challenges for clinical diagnosis and treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!